Pieris Pharmaceuticals surges on the stock market after agreement with Genentech
During yesterday's session, Pieris Pharmaceuticals soared in the financial markets after reaching a collaboration agreement with Genentech, in an operation that could be valued at $1.4 billion. This triggered its price by more than 103%, thus becoming one of the great protagonists of the session.
Specifically, this collaboration agreement focuses on several Genentech research programmes related to respiratory and ophthalmological problems that will use Pieris Pharmaceuticals' technology called Anticalin. In principle, Pieris will receive an initial payment of $20 million, although as we mentioned previously, this operation could reach $1.4 billion, depending on the results and objectives.
As we can see in the history of this company, during the last 5 years it has experienced strong volatility, although during the last months, the price has been trapped in a strong lateral range represented by the red and green bands that act as main levels of support and resistance.
After discovering the news yesterday, the price made a strong impulse from practically the lower band of this channel to exceed the medium-term downtrend line, closing at the highs of February 10 of this year at $3.42 per share in an area near the top of the canal.
This agreement can give the necessary momentum to this action to overcome said resistance level, so the breakdown of this would open the doors to a further upward journey to the level of $4.28, which acts as its second resistance.
On the other hand, after the strong momentum of yesterday's session, we cannot rule out a profit taking in the short term, which could cause a correction in the price in order to make a new impulse. Failure to break the upper band of the channel could prolong this important lateral movement over time.
Source: Pieris Pharmaceuticals daily chart from Admiral Markets MetaTrader 5 platform from August 31, 2018 to May 26, 2021. Done: May 26 at 12:00 CEST. Note: Past performance is not a reliable indicator of future results, or future performance.
Evolution of the last 5 years:
- 2020: -30.94%
- 2019: 36.09%
- 2018: -64.77%
- 2017: 437.29%
- 2016: -38.64%
With the Admirals Trade.MT5 account, you can trade Contracts for Differences (CFDs) of Pieris Pharmaceutical and more than 3000 stocks! CFDs allow traders to try to profit from the bull and bear markets, as well as the use of leverage. Click on the following banner to open an account today:
INFORMATION ABOUT ANALYTICAL MATERIALS:
The given data provides additional information regarding all analysis, estimates, prognosis, forecasts, market reviews, weekly outlooks or other similar assessments or information (hereinafter “Analysis”) published on the websites of Admiral Markets investment firms operating under the Admiral Markets trademark (hereinafter “Admiral Markets”) Before making any investment decisions please pay close attention to the following:
- This is a marketing communication. The content is published for informative purposes only and is in no way to be construed as investment advice or recommendation. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and that it is not subject to any prohibition on dealing ahead of the dissemination of investment research.
- Any investment decision is made by each client alone whereas Admiral Markets shall not be responsible for any loss or damage arising from any such decision, whether or not based on the content.
- With view to protecting the interests of our clients and the objectivity of the Analysis, Admiral Markets has established relevant internal procedures for prevention and management of conflicts of interest.
- The Analysis is prepared by an independent analyst, Roberto Rojas (analyst), (hereinafter “Author”) based on their personal estimations.
- Whilst every reasonable effort is taken to ensure that all sources of the content are reliable and that all information is presented, as much as possible, in an understandable, timely, precise and complete manner, Admiral Markets does not guarantee the accuracy or completeness of any information contained within the Analysis.
- Any kind of past or modeled performance of financial instruments indicated within the content should not be construed as an express or implied promise, guarantee or implication by Admiral Markets for any future performance. The value of the financial instrument may both increase and decrease and the preservation of the asset value is not guaranteed.
- Leveraged products (including contracts for difference) are speculative in nature and may result in losses or profit. Before you start trading, please ensure that you fully understand the risks involved.